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Abstract
Introduction: In 2005 the American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA)
published guidelines for managing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and
healthcare-associated pneumonia (HCAP). Although recommendations were evidence based, collective guidelines
had not been validated in clinical practice and did not provide specific tools for local implementation. We initiated
a performance improvement project designated Improving Medicine Through Pathway Assessment of Critical
Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) at four academic centers in the United States. Our
objectives were to develop and implement the project, and to assess compliance with quality indicators in adults
admitted to intensive care units (ICUs) with HAP, VAP, or HCAP.
Methods: The project was conducted in three phases over 18 consecutive months beginning 1 February 2006: 1)
a three-month planning period for literature review to create the consensus pathway for managing nosocomial
pneumonia in these ICUs, a data collection form, quality performance indicators, and internet-based repository; 2) a
six-month implementation period for customizing ATS/IDSA guidelines into center-specific guidelines via
educational forums; and 3) a nine-month post-implementation period for continuing education and data
collection. Data from the first two phases were combined (pre-implementation period) and compared with data
from the post-implementation period.
Results: We developed a consensus pathway based on ATS/IDSA guidelines and customized it at the local level to
accommodate formulary and microbiologic considerations. We implemented multimodal educational activities to
teach ICU staff about the guidelines and continued education throughout post-implementation. We registered 432
patients (pre- vs post-implementation, 274 vs 158). Diagnostic criteria for nosocomial pneumonia were more likely
to be met during post-implementation (247/257 (96.1%) vs 150/151 (99.3%); P=0.06). Similarly, empiric antibiotics
were more likely to be compliant with ATS/IDSA guidelines during post-implementation (79/257 (30.7%) vs 66/151
(43.7%); P = 0.01), an effect that was sustained over quarterly intervals (P = 0.0008). Between-period differences in
compliance with obtaining cultures and use of de-escalation were not statistically significant.
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Introduction
The American Thoracic Society and Infectious Diseases
Society of America (ATS/IDSA) published guidelines for
the management of hospital-acquired pneumonia
(HAP), ventilator-associated pneumonia (VAP), and
healthcare-associated pneumonia (HCAP) in 2005 [1].
The guidelines emphasize several major principles. First,
HAP, VAP, and HCAP should be treated promptly and
adequately because patients who experience delays in
appropriate therapy have increased mortality. Second,
local microbiologic data should be used to customize
management guidelines within centers. Third, excessive
antibiotic use should be avoided by accurately diagnos-
ing the infection, using culture results to de-escalate
initial therapy, and minimizing the duration of therapy.
Fourth, prevention strategies based on modifiable risk
factors for HAP should be implemented.
The goal of the ATS/IDSA guidelines is to provide an
organizational framework for initial evaluation and man-
agement of adults with bacterial HAP, VAP, or HCAP;
however, the authors acknowledged that the guidelines
had several limitations [1]. For example, individual
recommendations were based on the best available evi-
dence, but the impact of the collective guidelines on
clinical outcome had not been validated. Similarly, the
guidelines provide algorithms and management strate-
gies, but they do not provide specific tools for imple-
mentation at the local level.
Inspired by the ATS/IDSA guidelines [1] and the
desire to assess and improve outcomes in adults with
HAP in the intensive care unit (ICU), we initiated a per-
formance improvement project designated Improving
Medicine through Pathway Assessment of Critical Ther-
apy in Hospital-Acquired Pneumonia (IMPACT-HAP).
Our objectives were to develop, implement, and assess
this performance improvement project. To assess com-
pliance with management guidelines, we developed a
series of quality indicators and herein report our find-
ings before and after implementation of this perfor-
mance improvement project. Preliminary findings have
been previously reported [2-4].
Materials and methods
Participants
We conducted a multicenter performance improvement
project at four academic tertiary care centers in the Uni-
ted States. Participating centers were The Ohio State
University Medical Center, Columbus, Ohio; Henry
Ford Health System, Detroit, Michigan; University of
Miami Miller School of Medicine/Jackson Memorial
Hospital, Miami, Florida; and University of Louisville,
Louisville, Kentucky. The project was conducted in
selected adult medical ICUs at two centers (Columbus,
57 participating ICU beds and Miami, 18 beds) on the
basis of local staffing to conduct the project; and in all
adult ICUs at two centers (Louisville, 61 beds and
Detroit, 144 beds). The project was approved by the
institutional review board at each participating center;
each waived the need for informed consent.
Development of the performance improvement project
and educational efforts
We conducted a prospective performance improvement
project in three phases over 18 consecutive months
from 1 February 2006 through 31 July 2007. The first
phase was a three-month pre-implementation period.
Representatives from each center planned the project.
The IMPACT-HAP investigators evaluated the ATS/
IDSA guidelines [1] and reviewed the clinical literature
to develop a consensus pathway for the management of
HAP, VAP, and HCAP for ICU patients. We then
defined a series of quality performance indicators to
assess compliance with management guidelines. We cre-
ated a form to collect patient-level data (demographics,
laboratory, treatment, outcomes) and an Internet-based
repository to transfer the data to the IMPACT-HAP
study center at the University of Louisville.
The second phase was a six-month implementation
period. Principal investigators at each center formed
multidisciplinary teams to customize ATS/IDSA guide-
lines and create a local consensus pathway based on
their respective order sets, hospital formulary, and local
epidemiology (unit-specific antibiograms), including
consideration of center-specific resistance patterns. Edu-
cational efforts were initiated during implementation.
The third phase was a nine-month post-implementation
period with continued education and data collection.
Patient inclusion criteria and assessment
Adults in participating ICUs were eligible for inclusion
in the database if they met ATS/IDSA definitions for
HAP, VAP, or HCAP [1], including clinical suspicion of
evolving pneumonia while in the ICU, with new or pro-
gressive infiltrates on chest radiograph and at least two
of the following: new or increased cough, sputum pro-
duction, tracheal secretions, or shortness of breath; fever
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deterioration of pulmonary function [5]. Patients were
followed until hospital discharge, death, or Day 28,
whichever occurred first.
Comorbid conditions were prospectively defined and
extracted from patient records. Respiratory disease was
defined as a history of chronic obstructive pulmonary
disease. Renal disease was defined as a history of chronic
renal disease, or abnormal blood urea nitrogen and crea-
tinine. Cardiac disease was defined as systolic or diasto-
lic ventricular dysfunction by history, physical
examination, chest radiogram, or echocardiogram.
Immunosuppression was defined as active malignancy;
AIDS; end-stage renal, liver, or lung disease; steroids
(prednisone ≥10 mg for >7 days); or active chemother-
apy or radiotherapy within 30 days. Severe sepsis was
determined by calculation of the sepsis criteria and
organ dysfunction criteria [6], which were abstracted
from the chart at the time of enrollment or on Day 0.
Investigators completed a data collection form for
each patient. Principal investigators at each site reviewed
each form, added any missing data, and internally vali-
dated the information before transferring it via the
Internet to the repository. Validation of data quality was
also performed at the IMPACT-HAP study center.
Initial empiric therapy was classified as appropriate if
the isolated pathogen was susceptible to at least one
prescribed antibiotic. For the purpose of this analysis,
data from the first two phases were combined into one
nine-month period (that is, pre-implementation and
implementation (hereafter, pre-implementation period))
and compared with data from the third nine-month
phase (that is, post-implementation period).
Selection of empiric antibiotics was based on ATS/
IDSA guidelines [1] and the presence of risk factors for
multidrug-resistant organisms (MDROs). For example,
therapy was considered guideline compliant if, within
one day of pneumonia onset, patients with risk factors
for MDROs received dual gram-negative therapy plus
either linezolid or vancomycin for methicillin-resistant
Staphylococcus aureus (MRSA). Reasons for noncompli-
ance were recorded. Clinical outcome was categorized
on Day 14 as cure (complete resolution of signs and
symptoms of pneumonia), improvement (partial resolu-
tion), or failure (deterioration of signs and symptoms of
pneumonia). Clinical success was defined as cure or
improvement.
Statistics
Descriptive statistics were calculated for baseline demo-
graphics and severity-of-illness scores, compliance
with guidelines, and reasons for noncompliance in
patients enrolled during the pre-implementation and
post-implementation periods. Compliance with each
quality performance indicator was calculated as the per-
centage of patients who met the criteria for each indica-
tor based on the total number evaluable for each quality
indicator. Between-implementation differences were
compared using the Chi-square test or, if applicable,
Fisher’s exact test for categorical variables and, for con-
tinuous variables, the Student’s t-test for normally dis-
tributed variables and the Wilcoxon rank sum test for
non-normally distributed variables. P-values of ≤0.05
were considered to be statistically significant. All data
analyses were performed using SAS software, version 9.2
(SAS Institute Inc., 100 SAS Campus Drive, Cary, NC
27513-2414, USA).
Results
Consensus pathway
A consensus pathway was developed based on the prin-
ciples of the ATS/IDSA guidelines [1] for the manage-
ment of adults with HAP, VAP, and HCAP in the ICU
(Figure 1). Principal investigators, clinical pharmacists
and infection control practitioners from four academic
medical centers participated in three teleconferences
and a face-to-face consensus meeting. Principal investi-
gators had monthly teleconferences throughout the pro-
ject to maintain consensus; study coordinators had
teleconferences every two months.
On Day 0, patients with suspected nosocomial pneu-
monia (on the basis of the recognition of the presenting
signs and symptoms) were stratified by the presence or
absence of risk factors for MDROs. Patients without risk
factors for MDROs were to receive limited-spectrum
monotherapy, which included the following options: cef-
triaxone, fluoroquinolone, ampicillin/sulbactam, or erta-
penem. Most centers chose ceftriaxone or moxifloxacin,
except one center chose ampicillin/sulbactam or cef-
triaxone plus azithromycin or moxifloxacin.
Patients with risk factors for MDROs were to receive
expanded-spectrum combination therapy with dual
gram-negative coverage and either linezolid or vancomy-
cin as anti-MRSA therapy. Of the ATS/IDSA options for
primary gram-negative coverage (antipseudomonal
cephalosporin, antipseudomonal carbapenem, or b-lac-
tam/b-lactamase inhibitor), centers chose the following
three options: cefepime, imipenem or piperacillin-
tazobactam. Of the ATS/IDSA options for secondary
gram-negative coverage (antipseudomonal fluoroquino-
lone or aminoglycoside), most centers chose tobramycin
or amikacin.
The intent of the IMPACT-HAP pathway (Figure 1)
was to assist clinicians at the participating ICUs in recog-
nizing the signs and symptoms of suspected nosocomial
pneumonia and subsequently delivering antibiotics
compliant with the ATS/IDSA guidelines as quickly as
possible. Centers were permitted to adapt the consensus
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data determined by unit-specific antibiograms. Two cen-
ters had, as part of their educational tools, secondary
gram-negative therapy for all patients with risk factors
for MDROs and suspected HAP, VAP, or HCAP (see
example in Additional file 1). Two centers reserved sec-
ondary gram-negative therapy for VAP only, on the basis
of their local microbiology and the low risk of resistant
gram-negative pathogens in patients not requiring
mechanical ventilation. Although not in the ATS/IDSA
guidelines, colistin was prospectively deemed an accepta-
ble secondary gram-negative agent when carbapenem-
resistant Acinetobacter was of concern, as was the case in
one ICU.
On Day 3, antibiotic therapy was to be discontinued in
patients who met the criteria for short-course therapy as
described by Singh and colleagues [7]. Criteria for short-
course therapy were clinical pulmonary infection score
(CPIS) of ≤6 on days 0 and 3, and no sepsis, shock, or
immunosuppression. De-escalation was to be considered
on Day 3 if patients were not candidates for short-
course therapy. Criteria for de-escalation were clinical
improvement and cultures positive for a pathogen that
allowed antibiotics to be narrowed or focused based on
susceptibility. On Day 8, antibiotic therapy was to be
discontinued if the patient had improved clinically and
did not have cultures positive for Pseudomonas aerugi-
nosa or Acinetobacter spp. The total duration of antibio-
tics was not to exceed 14 days.
Implementation of the performance improvement project
We developed a data collection form to collect patient
demographics, comorbidities, physical examination,
laboratory, and chest radiograph findings; risk factors
for MDROs; and six quality performance indicators. We
tested the data collection form and data repository in
the first 30 patients, adjusted the form, and then used
the revised form for subsequent patients.
Quality performance indicators were expressed as per-
centages and calculated by dividing the number of
patients who met the criteria for the quality indicator by
the total number of patients in whom antibiotics for
DAY 0 RISK FACTORS FOR RESISTANT ORGANISMS 
Antibiotics within the prior 30 days of diagnosis of nosocomial pneumonia
Patient hospitalized >5 days before the diagnosis of nosocomial pneumonia was made
Bronchiectasis
Known family member with multidrug-resistant pathogen
Documented colonization with resistant organisms
Patient hospitalized for 2 days or more within prior 90 days of the diagnosis of nosocomial pneumonia was made
Residence in a nursing home or extended care facility
Chronic dialysis within the prior 30 days, home infusion therapy (including antibiotics), or home wound care
Immunosuppression (cancer, AIDS, ESRD, end stage liver disease, end stage COPD, steroids, chemotherapy/radiotherapy)
NOSOCOMIAL
PNEUMONIA
Monotherapy  To be completed by each institution
Combination Gram-positive coverage:  Linezolid or Vancomycin
therapy Gram-negative coverage: To be completed by 
each institution
DAY 3
CRITERIA FOR SHORT COURSE THERAPY OF NOSOCOMIAL PNEUMONIA
Clinical Pulmonary Infection Score (CPIS) d 6 on day 0 and day 3
No severe sepsis or shock on any day
No immunosuppression (e.g chemotherapy-induced neutropenia, other immunosuppressive state, transplant, or splenectomy patients)
CANDIDATE FOR SHORT 
COURSE THERAPY OF 
NOSOCOMIAL PENUMONIA
YES Discontinue antibiotics for nosocomial pneumonia
Risk factors for resistant 
organisms: NO
CANDIDATE FOR DE-ESCALATION THERAPY
If a pathogen was isolated: narrow spectrum to perform pathogen directed therapy
If cultures negative for MRSA: discontinue anti-MRSA therapy (Vancomycin or Linezolid)
If cultures negative for P. aeruginosa: discontinue 2nd agent (Tobramycin, Amikacin or Ciprofloxacin)
If cultures positive for P. aeruginosa: discontinue 2nd agent after patient clinically improved
Evaluate daily for Switch Therapy
DAY 8
CRITERIA FOR DISCONTINUATION OF ANTIBIOTICS
(daily evaluation)
3DWLHQWFOLQLFDOO\LPSURYHG
1R3DHUXJLQRVD LVRODWHG
1R$FLQHWREDFWHU LVRODWHG
NO
YES Stop antibiotics
Evaluate daily for the possibility to stop antibiotics
Total antibiotic therapy should not exceed 14 days
Risk factors for resistant 
organisms: YES
NO
Group I: Limited spectrum 
antibiotic therapy
Group II: Expanded spectrum 
antibiotic therapy
Figure 1 IMPACT-HAP consensus pathway for the management of nosocomial pneumonia in the intensive care unit.
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ted. The numerator for the first quality indicator (QI-1)
was the number of patients who met diagnostic criteria
for HAP, VAP, or HCAP and whose physicians recog-
nized and appropriately documented the risk factors for
HAP, VAP, or HCAP. The numerator for QI-2 was the
number of patients in whom respiratory (QI-2a) and
blood cultures (QI-2b) were obtained before antibiotics
were initiated. The numerator for QI-3 was the number
who received antibiotics compliant with ATS/IDSA
guidelines [1]. QI-4 was calculated by dividing the num-
ber of patients who received short-course therapy by the
total who were candidates for short-course therapy. QI-
5 was calculated by dividing the number who underwent
de-escalation on Day 3 by the total who were candidates
for de-escalation. QI-6 was defined by dividing the num-
ber of patients with clinical success at end of therapy or,
if the patient remained on antibiotics, on Day 14 by the
total who were evaluable for clinical outcome.
Educational efforts were started during the implemen-
tation phase. The principal investigators led a variety of
didactic forums including grand rounds, internal
medicine house staff lectures, infectious diseases and
pulmonary and critical care divisional conferences, ICU-
specific physician and nursing staff unit meetings, and
pharmacy and respiratory therapy conferences – all
emphasizing the ATS/IDSA guidelines [1] with the cen-
ter-specific management plan. We used multimodal
strategies, which included lectures utilizing a standar-
dized slide set, posters within the ICUs and patient
cubicles, emails to new ICU monthly attending physi-
cians and pulmonary fellows containing the center-spe-
cific flyer that could be folded into pocket-sized
references, and multiple personal interactions. Education
was continued informally throughout the post-imple-
mentation period primarily to target the newly rotating
house staff.
Patients
A total of 449 patients were captured in the Internet-
based repository; 17 were excluded because of missing
data. Of the remaining 432 patients, 274 were registered
during pre-implementation (1 February through
31 October 2006), and 158 during post-implementation
(1 November 2006 through 31 July 2007). Some differ-
ences existed in patient profiles when grouped by time
of registry (Table 1). A higher percentage of white
patients were registered during pre-implementation
(pre- vs post-implementation, 65.8% vs 57.6%; P =0 . 0 4
for race). Distribution of comorbidities was similar,
except that fewer patients had renal disease during pre-
implementation (15% vs 24.5%; P = 0.02). CPIS at base-
line and presence of severe sepsis were similar during
the two periods, but Acute Physiology and Chronic
Health Evaluation (APACHE) II score was lower during
pre-implementation (mean, 20.1 vs 21.6; P =0 . 0 3 ) .
Patients were also less likely to have a risk factor for an
MDRO during pre-implementation (92.6% vs 98.0%; P =
0.02).
Quality performance indicators
Evaluation of compliance with quality performance indica-
tors revealed some differences between periods (Table 2).
Specifically, empiric antibiotics were more likely to be
compliant during post-implementation with ATS/IDSA
guidelines (QI-3: pre- vs post-implementation, 30.7% vs
43.7%; P = 0.01) and with center-specific guidelines (35.8%
vs 51.0%; P = 0.002). Analysis of QI-3 at quarterly intervals
revealed improved compliance with ATS/IDSA guidelines
over time (P = 0.0008 for trend over time; Figure 2). The
most common reason for noncompliance with ATS/IDSA
guidelines during both periods was failure to use a second-
ary gram-negative agent (82/132 (62.1%) vs 56/71 (78.9%)).
Compliance with short-course therapy doubled during
post-implementation, but this improvement was not statis-
tically significant (25.0% vs 52.9%; P =0 . 1 0 )a n do n l ya
small number of patients (n = 37) were eligible for short-
course therapy during the project. Other between-period
differences in compliance with quality indicators were not
statistically significant.
Discussion
The IMPACT-HAP project demonstrated the feasibility
of developing a performance improvement project for
HAP, VAP, and HCAP based on the ATS/IDSA guide-
lines [1], while operationalizing and executing it at the
local level in multiple centers. The project included
features of other successful critical pathways [8-10],
such as appointing leaders to champion the project,
actively involving relevant stakeholders, and bench-
marking. Initial planning by representatives from each
center required three months to evaluate the clinical
literature, prepare a consensus pathway based on the
ATS/IDSA guidelines [1], and develop a data collection
form and Internet-based data repository. The pathway
was intentionally flexible to accommodate inter- and
intra-center differences. Multidisciplinary teams from
each center adapted the empiric therapy recommenda-
tions based on their local epidemiology and hospital
formulary, another feature of other successful projects
[11-14]. Implementation at the local level required
approximately six months. Different educational pro-
grams were offered to pulmonary/critical care and
infectious diseases attending physicians and fellows,
house staff, pharmacists, nursing and respiratory ther-
apy staff, including slide presentations for formal grand
rounds and lectures – all of which were supplemented
with printed materials to lead clinicians through the
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the ICU
Quality indicator Number/number evaluable
a (%) P-value
Pre-implementation (n = 274) Post-implementation (n = 158)
QI-1: Diagnostic criteria for HAP, VAP or HCAP met 247/257 (96.1) 150/151 (99.3) 0.06
QI-2a: Respiratory sample obtained before antibiotics 253/265 (95.5) 134/141 (95.0) 0.81
QI-2b: Blood culture obtained before antibiotics 214/264 (81.1) 121/141 (85.8) 0.23
QI-3: Empiric therapy compliant with ATS/IDSA guidelines [1]
b 79/257 (30.7) 66/151 (43.7) 0.01
QI-4: Short-course therapy performed 5/20 (25.0) 9/17 (52.9) 0.10
QI-5a: De-escalation possible 173/266 (65.0) 96/140 (68.6) 0.47
QI-5b: De-escalation possible and performed 56/173 (32.4) 36/96 (37.5) 0.40
QI-6: Clinical success at day 14 170/250 (68.0) 89/134 (66.4) 0.75
ATS, American Thoracic Society; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; IDSA, Infectious Diseases
Society of America; VAP, ventilator-associated pneumonia.
aAll patients were not evaluable for every quality indicator.
bEmpiric therapy compliant with center-specific guidelines: pre- vs post-implementation, 92/257
(35.8%) vs 77/151 (51.0%); P = 0.002.
Table 1 Baseline demographics and severity of illness in patients with HAP, VAP, and HCAP in the ICU, stratified by
enrollment period
Characteristic Number/number evaluable (%), unless otherwise indicated P-value
Pre-implementation
(n = 274)
Post-implementation
(n = 158)
Age in years, mean ± SD 57.1 ± 17.1 59.4 ± 16.8 0.20
Age <65 years 167/257 (65.0) 89/151 (58.9) 0.22
Male gender 173/257 (67.3) 93/151 (61.6) 0.24
Race 0.04
White 169/257 (65.8) 87/151 (57.6)
Black 79/257 (30.7) 50/151 (33.1)
Other 9/257 (3.5) 14/151 (9.3)
Weight in pounds, mean ± SD 182.7 ± 62.8 180.0 ± 65.5 0.68
Comorbid conditions
Respiratory 58/255 (22.8) 32/150 (21.3) 0.74
Renal 38/253 (15.0) 37/151 (24.5) 0.02
Cardiac 52/255 (20.4) 36/151 (23.8) 0.42
Malignancy 41/256 (16.0) 20/150 (13.3) 0.47
Immunosuppression
a 93/257 (36.2) 65/151 (43.0) 0.17
Severity of illness scores
APACHE II score, mean ± SD 20.1 ± 7.0 21.6 ± 7.7 0.03
CPIS, mean ± SD 6.2 ± 1.9 6.3 ± 1.7 0.59
Presence of severe sepsis 206/274 (75.2) 127/157 (80.9) 0.17
Risk factor for multidrug resistant pathogen
b
Any 238/257 (92.6) 148/151 (98.0) 0.02
Antibiotic within 30 days 154/236 (65.3) 90/148 (60.8) 0.55
Hospitalized ≥5 days before HAP antibiotics 166/238 (69.8) 79/148 (53.4) 0.001
Hospitalized ≥2 days within 90 days 92/238 (38.7) 81/148 (54.7) 0.01
Residence in nursing home or extended care 35/238 (14.7) 33/147 (22.5) 0.02
Chronic dialysis within 30 days 13/238 (5.5) 11/145 (7.6) 0.05
APACHE II, Acute Physiology and Chronic Health Evaluation II; CPIS, Clinical Pulmonary Infection Score; SD, Standard Deviation.
aImmunosuppression, active malignancy; AIDS; end-stage renal, liver, or lung disease; steroids (prednisone ≥10 mg for >7 days); or active chemotherapy or
radiotherapy within 30 days.
bThe three most common risk factors and those with significant between-group differences are listed.
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nia, assessing signs and symptoms, prescribing empiric
antibiotics, de-escalating antibiotics, and stopping
therapy.
We had initially planned to complete our educational
series at the end of the implementation period in order
to assess the impact of our initiative. Upon implementa-
tion, however, we recognized the need for continual
education to accommodate monthly rotations by house
staff, some of whom had not attended the formal grand
rounds or lectures. This is not unexpected, as recurrent
education is yet another feature of other successful
interventions [8,9,15,16]. This approach, however, has
implications for assessing compliance with quality
performance indicators and may have confounded our
ability to detect differences between pre- and post-
implementation periods.
Compliance with the quality performance indicators
related to making the clinical and microbiologic diagno-
sis of HAP, VAP, and HCAP (QI-1 and QI-2) exceeded
80%. Compliance was high before implementation of
our project and remained high during post-implementa-
tion. These findings are consistent with the aggressive
management of critically ill patients, the high quality of
care generally practiced in ICUs, and the knowledge
base at these four academic centers.
We found a statistically significant improvement in
administration of initial empiric therapy compliant with
ATS/IDSA guidelines (QI-3: pre- vs post-implementa-
tion, 30.7% vs 43.7%; P = 0.01). Notably, improvement
became evident during implementation and, impor-
tantly, was sustained throughout post-implementation.
The most common reason for noncompliance was fail-
ure to administer a secondary gram-negative agent,
which is consistent with the selective implementation of
the consensus pathway at participating centers in the
IMPACT-HAP study. Specifically, two centers did not
use the secondary gram-negative agent because their
local antibiograms indicated adequate coverage with the
primary gram-negative agent or reserved the secondary
gram-negative agent for patients with VAP. Therefore,
initial empiric therapy could be compliant with center-
specific guidelines but not with ATS/IDSA guidelines.
Others have also questioned the need for dual gram-
negative coverage in patients with risk factors for
MDROs because of concerns regarding potential renal
toxicity associated with aminoglycoside use and lack of
an additional benefit based on the local microbiology
[17]. A recent survey of more than 800 physicians pro-
vides further insight [18]. Although 71% were aware of
published guidelines, participants chose guideline-
concordant antibiotic regimens for HCAP only 9% of
Post-implementation phase 
Implementation phase 
Pre-implementation phase 
Quarter
Sixth Fifth Fourth Third Second First
60
50
40
30
20
10
0
Pre-implementation period Post-implementation period
Figure 2 Percentage of patients receiving initial empiric therapy compliant with ATS/IDSA guidelines at quarterly intervals . P = 0.0008
for trend over time.
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failed to choose a secondary antipseudomonal agent for
HCAP up to 36% of the time [18].
The next two quality performance indicators
addressed measures to avoid excessive antibiotic use.
Compliance with short-course therapy doubled during
post-implementation (QI-4: 25.0% vs 52.9%); however,
this difference was not statistically significant and less
than 10% of our patients met the criteria for short-
course therapy. Antibiotics were de-escalated on Day 3
based on microbiologic findings only in about one-third
of candidates for de-escalation during both periods (QI-
5b: 32.4% vs 37.5%). We did not capture reasons for fail-
ure to de-escalate, which merits further evaluation as
this is an additional area for potential improvement.
The last quality performance indicator, clinical success
at Day 14, remained unchanged (QI-6, 68.0% vs 66.4%).
Potential reasons for the inability to show changes in
clinical outcomes despite improvement in compliance
with empiric therapy include early adoption of the pro-
tocol during the implementation phase and the decision
to continue educational efforts throughout the study
despite our initial plans to complete our educational ser-
ies at the end of the implementation phase, as pre-
viously discussed. Another consideration is the high
clinical success rate observed during the pre-implemen-
tation period (reasonable for critically ill patients in the
ICU with HAP, VAP, and HCAP), making it difficult to
demonstrate further improvement.
While the compliance rates for certain quality perfor-
mance indicators including compliance with empiric
antibiotics appear low, our collective compliance rates
were generally consistent with those in studies comparing
outcomes before and after implementation of guidelines
for severe HAP and VAP [12,13,19] or studies validating
guidelines for HAP in the ICU [20-22]. Previous studies
had several limitations, such as being conducted at single
centers and usually having limited numbers of patients,
although Dellit et al. evaluated 819 patients [19]. The
three validation studies [20-22] did not include pre-
implementation data. Most studies evaluated the older
1996 ATS guidelines [23] or center-specific guidelines
[13,19,22]; only Ferrer et al. [20] evaluated the 2005
ATS/IDSA guidelines [1]. Compliance rates were variable
partly because of differences in study methods. In valida-
tion studies, compliance rates for empiric therapy were
49% [21] and 58% [20]. In the third validation study [22],
overall compliance with standard operating procedures
( S O P s )w a sr e p o r t e da se i t h e rh i g h e ro rl o w e rt h a n7 0 % .
Only 34% of patients were in the high compliance group
[22]. Compliance with empiric antibiotics was not
reported in the other studies [12,13,19].
Further studies are needed to validate the ATS/IDSA
guidelines for patients with HAP, HCAP, and VAP.
Some studies have shown that compliance with guide-
lines shortens the duration of mechanical ventilation
and ICU stay [22] or is associated with a higher percen-
tage of adequate antibiotics, which in turn leads to
reduced mortality [12]. In another study of HCAP,
receipt of empiric therapy not recommended by guide-
lines was independently associated with mortality after
adjusting for other variables [24]. Most studies, however,
fail to demonstrate significant correlations between
compliance and outcomes [13,19-21]. Our findings on
the relationships between compliance and outcomes are
reported separately [25]. Additional clinical findings
from IMPACT-HAP, such as a new score to predict
mortality [26] and the relationship of vancomycin mini-
mal inhibitory concentration (MIC) to mortality [27],
are also reported separately.
Our project had several limitations. Most importantly,
the participants were adults in multiple ICUs, an inher-
ently complex group with many comorbidities. This was
a non-randomized, observational study with the natural
limitations of real-world academic medical center prac-
tices. However, data from IMPACT-HAP were for the
most part prospectively collected and validated before
entry into the data repository. Another limitation was
the inability to capture all patients admitted to these
ICUs during the study period. Specifically, we enrolled
as many patients as possible but missed some, especially
those admitted on weekends or discharged from the
ICU before we could learn of them. Furthermore,
patient enrollment was not evenly distributed among
centers. For these reasons, our findings may not be gen-
eralizable to other ICU populations or patients treated
outside the ICU setting. Finally, feedback was not pro-
vided to investigators until after the post-implementa-
tion period was completed. Real-time feedback might
have improved compliance with ATS/IDSA guidelines
and other quality indicators.
Conclusions
Developing a multi-center performance improvement
project for implementation of the ATS/IDSA guidelines
for HAP, HCAP, and VAP is feasible. Important features
of IMPACT-HAP included flexibility to accommodate
expected differences in unit-specific epidemiologic data
and hospital formularies, ongoing education, and bench-
marking. Diagnostic work-ups were performed accord-
ing to ATS/IDSA guidelines for most patients. Empiric
antibiotics were compliant with the guidelines in less
than half of the patients; however, improvement in com-
pliance during post-implementation was statistically sig-
nificant and was sustained. Similarly, short-course
therapy and de-escalation were performed in no more
than half of eligible patients. The low overall perfor-
mance in these areas despite educational interventions
Mangino et al. Critical Care 2011, 15:R38
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stand how to influence physician behavior. Additional
studies are also needed to validate ATS/IDSA guidelines
for HAP, HCAP, and VAP.
Key messages
￿ A performance improvement project for imple-
menting ATS/IDSA guidelines for HAP, VAP, and
HCAP should be flexible enough to accommodate
local epidemiology and hospital formulary
considerations.
￿ The project should include leaders who can cham-
pion the initiative and should engage relevant
stakeholders.
￿ Educational efforts should be repeated routinely
and continued indefinitely in training centers.
￿ Benchmarking should be performed to provide
feedback to participating centers.
Additional material
Additional file 1: Center-specific algorithm.
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